
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics is viewed favorably because oral elraglusib could materially improve exposure versus the IV formulation, with PK modeling suggesting 1–2 tablets daily may reach targeted levels and preclinical bioavailability above 95%. FDA clearance for the Phase 1/2 study, following the April 2026 IND filing, supports a potential 2H26 start and a relatively short path to pivotal development by 2H27 if safety and efficacy hold. The pediatric neuroblastoma program adds optionality, with 53% clinical response or disease control in 10 of 19 heavily pretreated patients, and a possible rare pediatric disease PRV worth approximately $150M to $200M, though additional funding may be needed.
Bears say
Actuate Therapeutics is a clinical-stage biopharmaceutical company with no revenues in 1Q26 or 2Q26, underscoring a dependence on future clinical success rather than current commercial cash flow. Its losses remain persistent at $0.24 per diluted share in 1Q26 and $0.20 in 2Q26, while projected 2026 net losses of $0.84 and $0.61 per diluted share highlight continuing operating burn. Liquidity is also strained, with cash and cash equivalents falling from $8.1M at the end of 1Q26 to $4.44M at the end of 2Q26, and management indicating funds are not sufficient to support operations beyond September 2026.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Actuate Therapeutics Inc (ACTU) Forecast
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares